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In this study we report on the isolation and charac-
terization of a nonepithelial, nontumorigenic cell
type (BCC1) derived from a basal cell carcinoma
from a patient. The BCC1 cells share many charac-
teristics with dermal ®broblasts, such as the expres-
sion of vimentin, lack of expression of cytokeratins,
and insensitivity to agents that cause growth inhib-
ition and differentiation of epithelial cells; however,
signi®cant differences between BCC1 cells and ®bro-
blasts also exist. For example, BCC1 cells are stimu-
lated to undergo DNA synthesis in response to
interferon-g, whereas dermal ®broblasts are not. More-
over, BCC1 cells overexpress the basal cell
carcinoma-speci®c genes ptch and ptch2. These data
indicate that basal cell carcinomas are associated with
a functionally distinct population of ®broblast-like cells
that overexpress known tumor-speci®c markers (ptch
and ptch2). Key words: epithelial±mesenchymal transition/
epithelium/skin cancer. J Invest Dermatol 118:859±865, 2002
B
asal cell carcinomas (BCC) are the most common
tumor type in humans, with incidence rates as high as
1±2% per year in some areas of Australia (Giles et al,
1988; Buettner and Raasch, 1998). These tumors are
unusual in that they rarely metastasize or result in the
patients' death, yet they may be locally invasive causing signi®cant
morbidity. Whereas BCC have been well described at the
histopathologic level (Weedon, 1997) it is only recently that some
of the molecular events underlying BCC development have been
reported. For instance, in normal epidermis the plasma membrane
receptors ptch and smoh interact to suppress the activation of the Gli
family of transcription factors (Johnson and Scott, 1998); however,
in the presence of one of the hedgehog family of ligands (shh, dhh,
ihh), the suppression of smoh, by ptch, is relieved and trans-activation
of Gli-responsive genes occurs [e.g., transforming growth factor
(TGF)-b or ptch; Johnson and Scott, 1998]. Thus, it has been both
predicted and observed, that loss of function mutations in ptch or
smoh leads to activation of the ptch/smoh/Gli signaling pathway and
increases in ptch mRNA levels (Kallassy et al, 1997; Unden et al,
1997; Wolter et al, 1997). Furthermore, mutations in the patched
(PTCH) gene in both sporadic BCC and in lesions from patients
with familial BCC (Gorlin's syndrome) is associated with increases
in ptch mRNA and a high incidence of BCC (Hahn et al, 1996b;
Johnson et al, 1996). The causal nature of increased ptch in BCC
genesis has been corroborated in transgenic animal models
overexpressing mutated members of the ptch/smoh signaling
pathway (Fan et al, 1997; Oro et al, 1997; Grachtchouk et al,
2000). More recently, patched 2 (PTCH2), a homolog of the
PTCH gene was isolated and mutations may also be involved in
tumor development (Zaphiropoulos et al, 1999; Smyth et al, 1999).
Despite the above ®ndings, it is unlikely that alterations in the
patched/smoothened signaling pathway are the only signi®cant
functional mutation in BCC, as it does not explain the different
histologic subtypes of BCC or their different behavior in vivo.
Other molecular changes reported in BCC include loss of function
mutations of p53 (Rady et al, 1992; Moles et al, 1993; Ziegler et al,
1993), increased expression of Bcl-2, fas ligand, and TGF-b, and
decreased expression of laminin 5 and fas (Sollberg et al, 1992,
1994; Buechner et al, 1997; Verhaegh et al, 1997); however, the
functional signi®cance (if any) of the altered expression of these
molecules in BCC development is unclear.
Another unresolved controversy, pertaining to BCC, is the cell
of origin for these tumors. For instance, there is evidence to suggest
a follicular origin of BCC (Markey et al, 1992). Alternatively, there
is also evidence to suggest BCC are derived from the stem cell
population of the pilosebaceous unit (Ponten et al, 1994).
Complicating these hypotheses is the growing body of evidence
indicating that nonepithelial components of skin are also important
regulators of keratinocyte function (Matsuzaki and Yoshizato,
1998; Kishimoto et al, 2000; Szabowski et al, 2000). These studies
suggest that the pathologic features attributed to BCC may not be
solely due to lesional events in the keratinocyte population but may
also re¯ect aberrations in epithelial±mesenchymal interactions. This
introduces the formal possibility that alterations in the nonepithelial
component of the skin may contribute to BCC development.
Whereas such a phenomenon was recently reported for ductal
breast carcinoma (Shekhar et al, 2001), proof of principle for this
notion in BCC has not been reported yet.
MATERIALS AND METHODS
Tissue culture Isolation and culture of primary cultures of human
epidermal keratinocytes (HEK) and human dermal ®broblasts (HDF)
have been described previously (Jones et al, 1997; Dahler et al, 1998).
Culture of HaCaT cells has also been described (Dicker et al, 2000a;
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Popa et al, 1999). Isolation of the BCC1 cell line from a patient BCC
was as follows. A nodular sample of BCC was dissected free from the
overlying normal epidermis and adjacent stroma using an inverted
dissecting microscope, then cut into cubes of approximately 1 mm3.
These were placed on to a 10 cm2 tissue culture dish and moistened
with 200 ml of 3:1 medium (Jones et al, 1997; Dulbecco's minimal
Eagle's medium/Hams F12, 3:1 vol/vol supplemented with 10,000 units
penicillin/streptomycin per ml, 5 mg transferrin per ml, 5 mg insulin per
ml, 8.4 ng cholera toxin per ml, 240 ng hydrocortisone per ml, 34 mg
adenine per ml, and 10 mg gentamycin per ml in the absence of
epidermal growth factor for 48 h). The ®nal calcium concentration of
this media was 1.9 mM, which was not conducive to the serial passaging
of keratinocytes. Dishes were placed in an incubator at 37°C for 30 min
to allow attachment of the tissue lumps. Tissue was then covered with
1 ml of 3:1 medium for 72 h. This medium was then replaced with 3:1
medium supplemented with 2 ng epidermal growth factor per ml and
medium changed every 2±3 d. Macroscopically visible keratinocyte
colonies were scraped off the dish when present. Contaminating
®broblasts were minimized by brief trypsinization of the cultures
(Grando et al, 1996). Cells were either serially passaged 1:6 or frozen at
2 3 106 cells per ml in 3:1 medium supplemented with 10% dimethyl
sulfoxide.
In some instances organotypic raft cultures of keratinocytes were made
using either HDF or the BCC1 cells as the dermal cellular component as
described (Dicker et al, 2000b). In some instances, keratinocytes, HDF
and BCC1 cells were treated with conditions that cause keratinocyte
differentiation such as, 12-O-tetradecanoyl phorbol-13-acetate (50 ng per
ml), interferon-(IFN)-g, 100 units per ml or growth to con¯uence (48 h;
Jones et al, 1997). Growth inhibition and differentiation were later
con®rmed by thymidine incorporation (Saunders et al, 1993a; Dahler et
al, 2001) and transglutaminase type 1 expression (Dicker et al, 2000a;
Saunders et al, 1993b; Saunders and Jetten, 1994).
RNA extraction and reverse transcription±PCR analysis Expression
levels for b-actin, transglutaminase type 1 (Dicker et al, 2000a; Popa et al,
1999), Ptch, and Ptch2 were estimated by reverse transcription±PCR
under linear conditions with respect to cycle number and template
concentration (Popa et al, 1999). Oligonucleotides for estimating the
expression of Ptch and Ptch2 (a generous gift from Dr Ian Smyth,
Institute for Molecular Biosciences, Brisbane, Australia) were as follows:
5¢Ptch CCCTGCAGACCATGTTC; 3¢PTCH, AGAAATGG-
CAAAACCTGAGTT; 5¢PTCH2, GCTGGCCTATGCCTGTGT; 3¢P-
TCH2, GGCGTGGCGCCGCCGTAGGTCCAGG.
Ampli®cation conditions for Ptch and Ptch2 were 94°C for 40 s, 55°C
for 40 s and 72°C for 40 s. Analysis of the presence of the gGli1 splice
variant, by reverse transcription±PCR, has been previously described by
us (Wang and Rothnagel, 2001).
Protein isolation, western blotting, and immunohistochemistry Total
cellular protein was isolated from trypsinized cells as described
(Brinkmann et al, 2001; Dahler et al, 2001). Five micrograms of total
protein was electrophoresed on a 7.5% sodium dodecyl sulfate±
polyacrylamide gel electrophoresis gel and blotted on to PVDF
membrane. Blots were then probed with an epithelial speci®c pan
cytokeratin antibody (AE1/AE3; ICN, Sydney, NSW, Australia), a
keratinocyte-speci®c antibody against cytokeratins 5/6 (Santa Cruz,
Brisbane, QLD, Australia) or a mesenchymal-speci®c antibody against
vimentin (Sigma-Aldrich, Sydney, NSW, Australia). All antibodies were
used at a dilution of 1:5000 and were visualized by chemiluminescence
(Dahler et al, 2001). Actin levels were examined by western blot to
check for loading equality (1:2000, Santa Cruz, Brisbane, QLD,
Australia). Immunohistochemical detection of cytokeratins in paraf®n
embedded sections used the AE1/AE3 antibody (1:200) and was
visualized with 1:1000 HRP-conjugated anti-mouse antibody (Dako,
Sydney, NSW, Australia).
Tumor injection studies and DNA ploidy analysis Tumor injection
studies with 2 3 106 cells of HDF, BCC1 or the tumorigenic SCC25
cell line were carried out in nude mice by subcutaneous injection as
described (Dicker et al, 2000b). DNA ploidy of BCC1 cells and HDF
were examined by staining cells with propidium iodide then analyzing
them by ¯ow cytometry on a Coulter EPICS Elite EPS (Coulter Corp,
Hialeah, FL) equipped with a 488 nm argon laser using a 610 band pass
®lter and standardized protocols (Shapiro, 1995; Brinkmann et al, 2001).
Data from 10,000 events per sample were collected.
RESULTS
Isolation and tumorigenicity of BCC1 cells Explant cultures
of BCC cells contained a central cluster of cells that were epithelial
in appearance with an expanding edge of spindle-shaped cells
(Fig 1A). Unlike ®broblasts, these spindle-shaped cells did not
form focal colonies or ``whirls'' of spindle-shaped cells but instead
remained as a single cell layer at the expanding edge of the explants.
When selectively passaged, these spindle-shaped cells remained
®broblast-like until con¯uence, when they became epithelioid in
appearance (Fig 1A). Unlike primary keratinocytes and ®broblasts,
Figure 1. BCC1 cells have a distinct morphology in vitro and are
diploid. (A) Explant culture of BCC1 cells from a tumor nodule placed
in culture. Note the epitheliod morphology of the BCC1 cells in the
con¯uent portion of the explant and the spindle-shaped morphology on
the expanding edge of the explant. Scale bar: 100 mm. (B)BCC1 cells in
passage 3 were trypsinized, ®xed, and stained with propidium iodide
ready for ploidy analysis by ¯uorescence-activated cell sorter.
Fluorescence pro®le of the cells is shown. The 2n and 4n components of
the G0/G1 phase cells and the G2/M phase, respectively, of normal
®broblasts is shown for comparison.
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cells from a BCC (either in initial culture or in subsequent passages)
were unable to proliferate in keratinocyte serum-free medium (data
not shown). We have selected one explant culture for further
analysis. This cell type is referred to as BCC1.
As BCC1 cells were initially isolated from a patient tumor we
took passage three cells and examined their tumorigenic potential.
Injection of BCC1 cells, ®broblasts, or keratinocytes subcuta-
neously into 12 wk old nude mice did not give rise to tumors after
12 wk. In contrast, the squamous cell carcinoma line, SCC25,
formed macroscopically visible tumors after 12 wk (not shown). In
a further test of the transformed phenotype of the BCC1 cells we
examined their ploidy. Although the majority of BCC are diploid,
the more invasive forms are frequently aneuploid. Comparison of
the ploidy in propidium iodide stained BCC1 cells and normal
HDF indicated that the BCC1 cells were diploid (Fig 1B).
Ptch and Ptch2 mRNA expression in BCC1 cells As BCC1
cells, in culture, appeared dissimilar to either ®broblasts or
keratinocytes we decided to examine the expression of BCC-
speci®c (ptch, ptch2), keratinocyte-speci®c (AE1/AE3, cytokeratins
5/6) and mesenchyme-speci®c (vimentin, Franke et al, 1978)
markers in HEK, HDF, and BCC1 cells (Fig 2A, B).
Overexpression of ptch has been reported previously in sporadic
and familial forms of BCC (Kallassy et al, 1997; Unden et al, 1997;
Wolter et al, 1997). Reverse transcription±PCR analysis of mRNA
expression levels for ptch and ptch2 indicated that both genes were
overexpressed in the HaCaT keratinocyte cell line (Fig 2A), used
as a positive control in this study (Kallassy et al, 1997), compared
with normal keratinocytes. The BCC1 cells expressed
Figure 2. BCC1 cells overexpress ptch but not epithelia-speci®c
cytokeratins. (A) Proliferating ®broblasts (HDF), keratinocytes (HEK),
BCC1 cells, or HaCat cells were harvested and RNA isolated and
subjected to reverse transcription±PCR analysis for the expression of ptch
and ptch2 mRNA. Data presented as mean 6 SEM derived from three
independent experiments. Data expressed as a percentage of that of
HEK. *Denotes signi®cant difference (p < 0.05) to HEK as determined
by t test. All data were normalized to the expression of actin. (B)
Proliferating keratinocytes (HEK), BCC1 cells, or HDF were examined
for the presence of the g splice variant of Gli1 by reverse transcription±
PCR. The 75 bp PCR product, diagnostic of the presence of the g
transcript, is shown as is the water control (±) and a BCC tumor sample
positive control (+). (C) Protein was isolated from con¯uent
keratinocytes (HEK), ®broblasts (HDF) and BCC1 cells and 10 mg
subjected to western blot analysis for the expression of epithelial-speci®c
markers (cytokeratins 5/6 or pancytokeratins AE1/AE3) or
mesenchymal-speci®c markers (vimentin). Actin expression is shown to
con®rm equal loading of the lanes.
Figure 3. BCC1 cells are derived from a cytokeratin-positive
BCC. Paraf®n section of the BCC of origin of the BCC1 cells was
stained with hematoxylin and eosin (A) or with an anti-AE1/AE3
pancytokeratin antibody (B; 1:200). Scale bar: 100 mm. Inset is the
negative control.
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approximately 2.4-fold more ptch than HEK and HDF, which is
consistent with the 2±7-fold increase found in primary samples of
BCC relative to normal skin (Kallassy et al, 1997; Unden et al, 1997;
Wolter et al, 1997). The expression of ptch2, while increased (1.7-
fold), was not signi®cantly different to that of HEK but was
signi®cantly increased above that of HDF (approximately 4.4-fold,
Fig 2A). The overexpression of ptch in BCC1 cells is consistent
with the overexpression caused by a mutation in the patched/
smoothened pathway, observed in BCC in vivo (Kallassy et al, 1997;
Unden et al, 1997; Wolter et al, 1997). The g splice variant of Gli1
has been previously shown to be tissue speci®c in its expression
(Wang and Rothnagel, 2001) and the presence of this splice variant
in the BCC1 cells is consistent with either a BCC origin or the
proliferative status of the cells (Fig 2B); however, single-stranded
conformational polymorphism analysis of the Ptch and Smoh genes
in BCC1 cells did not identify any mutations (not shown).
The overexpression of ptch has not been reported in the
nonepithelial component of BCC before and thus we were curious
as to the origin of the BCC1 cells. The epithelial-speci®c markers
AE1/AE3 and cytokeratins 5 and 6 were only detected in HEK,
whereas the mesenchymal-speci®c marker, vimentin, was expressed
in both HDF and the BCC1 cells (Fig 2C). Grando et al (1996) has
shown that cells cultured from BCC express low levels of
immunoreactivity with the AE1/AE3 antibody but high reactivity
to the cytokeratin 5/6 antibody. These data indicate that BCC1
cells express both mesenchymal-speci®c markers (vimentin) and
BCC epithelial-speci®c markers (ptch and ptch2). As it has been
reported that BCC can sometimes be cytokeratin negative (Jones et
al, 1989; Asada et al, 1992; Barbaud et al, 1998) we examined the
cytokeratin staining (AE1/AE3) of the BCC from which BCC1
cells were derived (Fig 3). Figure 3 demonstrates that the original
BCC was positive for cytokeratin staining, which strongly suggests
that the BCC1 cells are not epithelial in origin.
BCC1 cells are functionally dissimilar to HEK in vitro As the
BCC1 cells shared some properties with both HEK and HDF we
examined the ability of the BCC1 cells to respond to stimuli that
cause growth arrest and squamous differentiation in keratinocytes
but not ®broblasts. Keratinocytes treated with the protein kinase C
activator, 12-O-tetradecanoyl phorbol-13-acetate (50 ng per ml for
48 h) or IFN-g (100 U per ml for 48 h) or grown to con¯uence
(48 h) undergo a profound growth arrest (Fig 4A) and induce the
expression of squamous differentiation-speci®c genes such as
transglutaminase type 1 (Fig 4B). In contrast, proliferation, in
®broblasts and BCC1 cells, was inhibited only in contact-inhibited
cells (con¯uent) and in no instance did the cells undergo squamous
differentiation. Of particular interest was the observation that,
unlike ®broblasts, the BCC1 cells increased proliferation in a time-
and concentration-dependent manner in response to IFN-g
(Fig 3C). This result was not expected and indicated that the
BCC1 cells were biologically distinct from keratinocytes and
®broblasts. Because of this difference we decided to examine
whether the BCC1 cells could support the growth of keratinocytes
in an organotypic raft culture (Fig 5). Raft cultures represent an
Figure 4. BCC1 cells are functionally distinct to epidermal
keratinocytes and dermal ®broblasts. Proliferating keratinocytes
(HEK), ®broblasts (HDF), and BCC1 cells were either left untreated
(Prol) or were treated with 50 ng per ml 12-O-tetradecanoyl phorbol-
13-acetate for 48 h, 300 units per ml IFN-g for 48 h or were left to
grow to con¯uence (Con¯) at which time estimates of DNA synthesis
(A) or transglutaminase type 1 mRNA expression (B) were measured.
DNA synthesis was estimated by 3H-thymidine incorporation and
transglutaminase type 1 mRNA expression was estimated by reverse
transcription±PCR analysis. (C) BCC1 cells were treated with either
300 units per ml of IFN-g for the indicated times or were treated with
varying concentrations of IFN-g for 48 h. DNA synthesis was then
estimated as described above. All data are presented as mean 6 SEM of
triplicate determinations. Data presented as a percentage of the untreated
control in all experiments.
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``in vivo equivalence assay'' in which a dermal substitute comprising
collagen and ®broblasts support the strati®ed growth of
keratinocytes at the air/liquid interface (Dicker et al, 2000b).
Normal ®broblasts are able to support the growth of a strati®ed
squamous epithelium (Fig 5A). BCC1, when used with collagen as
the dermal component, were also able to support the growth of a
strati®ed squamous epithelium (Fig 5B). In contrast, keratinocytes
grown on a dermal component lacking ®broblasts were not able to
form a strati®ed squamous epithelium (Fig 5C). Whereas our data
suggest that the BCC1 cells, isolated from a BCC, share many
biologic properties with ``normal'' dermal ®broblasts the data also
indicate that they possess biologic attributes not shared by
®broblasts (Table I).
DISCUSSION
This study reports on the isolation of a nonepithelial cell type
(BCC1), which overexpresses ptch, from a BCC. The BCC1 cells
shared many similarities with normal ®broblasts but also appeared to
be biologically dissimilar, with respect to their responsiveness to the
immunomodulatory molecule, IFN-g, and their expression of ptch
and ptch2 mRNA. The isolation of these cells from a patient BCC
may have implications for our understanding of BCC genesis.
The data presented in this study is most consistent with a
nonepithelial cell lineage for the BCC1 cells. BCC1 cells
overexpress ptch mRNA at the high levels characteristically seen
in patient samples of BCC (Gailani et al, 1996; Hahn et al, 1996a,
>b; Kallassy et al, 1997; Unden et al, 1996, 1997). Furthermore,
BCC1 cells overexpress ptch2 compared with ®broblasts, although
not when compared with keratinocytes. In isolation, the over-
expression of ptch and ptch2 would be considered characteristic of an
epithelial origin for the BCC1 cells. The BCC1 cells, however, did
not express epithelial-speci®c or keratinocyte-speci®c cytokeratins
in vitro or in vivo and did not undergo growth arrest and
differentiation in response to differentiation-inducing stimuli.
These data are not consistent with an epithelial origin for the
BCC1 cells. Whereas it has been reported that cytokeratin staining
is absent in some BCC (Jones et al, 1989; Asada et al, 1992; Barbaud
et al, 1998) this was not the case in the present study. Furthermore,
the BCC1 cells express vimentin and are able to support the
strati®cation of keratinocytes in an organotypic raft culture, which
are attributes more consistent with a ®broblastic phenotype than an
epithelial phenotype.
Although the BCC1 cells share many characteristics with dermal
®broblasts they are also dissimilar suggesting that they may represent
a biologically distinct subset of HDF such as: (i) a stem cell; (ii) a
dermal papilla cell; (iii) a cell recruited to the tumor; or (iv) a
transformed ®broblast. Whereas it was not central to this study to
discriminate between these possibilities, it is important to note that
dermal papilla cells and dermal ®broblasts have been shown to be
functionally distinct (Matsuzaki and Yoshizato, 1998; Kishimoto et
al, 2000; Sleeman et al, 2000) as have ®broblasts from different sites
of the body (Bernacki et al, 1992). Moreover, ®broblasts surround-
ing the pallisading epithelial cells in a BCC are thought to be
functionally distinct from the surrounding dermal ®broblast
population. These data suggest that a ®broblast-like cell type
(BCC1) may be preferentially associated with BCC in vivo.
Although unlikely, it remains a formal possibility that the BCC1
cells are transformed ®broblasts or are the result of an epithelial±
mesenchymal transition. Epithelial±mesenchymal transitions have
been shown to be stimulated by TGF-b1 in keratinocytes during
Figure 5. BCC1 cells are able to support the growth of
keratinocytes in an organotypic raft culture model. Raft cultures
were prepared using either (A) dermal ®broblasts, (B) BCC1 cells, or (C)
no cells within the collagen matrix. All rafts have similar numbers of
keratinocytes plated on top of the collagen matrix and have been treated
in an identical manner. Scale bar: = 100 mm. Sections have been stained
with hematoxylin and eosin. For orientation the sections have been
labeled d = dermal equivalent, e = epithelial component, sc = stratum
corneum layer.
Table I. Summary of differences between epidermal
keratinocytes, dermal ®broblasts, and BCC1 cells
HEK HDF BCC1
Ptch mRNA expression + + ++
Ptch2 mRNA expression ++ + ++ ++
Cytokeratin expression ++ + ± ±
Vimentin expression ± ++ ++
Transglutaminase type 1
mRNA expression
+ ±
±
Ploidy Normal Normal Normal
Support strati®ed Not Yes Yes
Epithelial growth applicable
In vivo tumorigenicity No No No
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the latter phases of transformation (Cui et al, 1996). Interestingly,
one of the downstream targets of ptch is TGF-b (Johnson et al,
1995; Gailani et al, 1996) and so it is possible that the BCC1 cells
are the product of a neoplastic transition of epithelial cells to
mesenchymal cells induced by tumor-speci®c factors. Supporting
this is the observation that TGF-b levels are increased in stroma
surrounding tumors (Stamp et al, 1993; Schmid et al, 1996).
Whereas we cannot exclude this possibility, it is not consistent with
our observation that the BCC1 cells are not tumorigenic in vivo.
The isolation of a ®broblast-like cell type from a patient's BCC
raises some interesting questions as to its potential role in
tumorigenesis. At present it is unclear whether the presence of
BCC1 cells is critical to tumor formation, the isolation of these cells
raises several questions, such as: Do BCC1 cells have an inductive
effect on keratinocytes in forming tumors? A precedent for such a
mechanism is seen in hair plakode formation. Moreover, it is now
evident that the substratum, or factors secreted from ®broblasts, are
essential to epithelial differentiation and keratinocyte strati®cation
in vitro and in vivo (Rearick and Jetten, 1989; Szabowski et al, 2000).
Additionally, the observation that the BCC1 cells undergo
hyperproliferation in response to IFN-g raises the possibility that
some of the tissue remodeling that occurs during BCC formation
may be due to the stimulation of the in vivo equivalent of the BCC1
cells by in®ltrating activated T cells that secrete IFN-g and are
frequently observed in BCC interstitium (Kooy et al, 1998). This
point is most relevant as it has been reported that epithelial BCC
cells lose responsiveness to IFN-g (Kooy et al, 1998).
It is unclear whether the overexpression of ptch in BCC1 cells is
due to loss of function mutations in the PTCH gene or due to
other mechanisms. For instance, we found no evidence of a
mutation in ptch by single-stranded conformational polymorphism
analysis (not shown); however, the unreliability of single-stranded
conformational polymorphism (approximately 40% accurate) does
not allow us to conclusively exclude the possibility of a loss of
function mutation in the PTCH gene. Moreover, whereas
overexpression of ptch is consistent with a defect in the Ptch/
Smoh/Gli signaling pathway we have not identi®ed the point in the
pathway responsible. For instance, the expression of the g splice
variant for Gli1 is consistent with a BCC origin and is associated
with a stimulation of the Ptch/Smoh/Gli signaling pathway (Wang
and Rothnagel, 2001); however, the g splice variant is also present
in proliferative cells (Wang and Rothnagel, 2001). Thus, further
studies on this signaling pathway are required.
In conclusion, this study has isolated a ®broblast-like cell type
(BCC1) that overexpresses ptch and is functionally distinct from
normal keratinocytes and normal ®broblasts. Preliminary charac-
terization suggests that these cells are not tumorigenic and are not
the product of an epithelial±mesenchymal transformation. Further
genetic analysis is in progress to determine the genetic differences,
and perhaps fate, of the BCC1 cells.
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